Crixivan

(Indinavir sulfate)

ApprovedSmall molecule

Indinavir sulfate is used to treat HIV (human immunodeficiency virus) infection by helping to slow or stop the virus from multiplying in the body. It is typically used as part of a combination therapy with other HIV medications.[2] Crixivan is currently approved and in use across 5 indications[4].[1]

Crixivan is one of 188 small molecule programs targeting HIV infection. It is currently in Approved.

Indications

Total Trials

Active Trials

187

Competitors

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionUnknown

HemophiliaActive, not recruiting

HIV-1 InfectionActive, not recruiting

Ewing SarcomaActive, not recruiting

RhabdomyosarcomaActive, not recruiting

HIV InfectionPreclinical

Unknown

HemophiliaApproved

Active, not recruiting

HIV-1 InfectionPreclinical

Active, not recruiting

Ewing SarcomaPhase 2

Active, not recruiting

RhabdomyosarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

Crixivan

Merck & Co.

Approved

6 2

Sunlenca

Gilead

Phase 3

1 3

Intron a

Merck & Co.

Phase 3

1 4

Megace

PEG-Intron

Betaseron

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

2 8

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 3

1 9

Buprenorphine/naloxone

Astellas

Phase 3

1 10

TWINRIX™

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Effectiveness23 trials

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002235·6 enrolled

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000850·108 enrolled

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

Terminated·AAgouron Pharmaceuticals·N/A·NCT00006326·60 enrolled

Show 20 more trials

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000922·1,710 enrolled

The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002376·540 enrolled

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002451·8 enrolled

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000916·399 enrolled

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002442

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002179·200 enrolled

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002241·80 enrolled

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000901·24 enrolled

The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00005118·100 enrolled

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000896·24 enrolled

The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Completed· Gilead logo

Gilead·Phase 2·NCT00002379·100 enrolled

A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002430·220 enrolled

A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002452·30 enrolled

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002387·80 enrolled

Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002375·24 enrolled

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002361·30 enrolled

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000914·800 enrolled

The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002443·780 enrolled

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00002371·80 enrolled

A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

Suspended· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002424·186 enrolled

Drug11 trials

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002410

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002168·200 enrolled

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

Completed· GSK logo

GSK·Phase 2·NCT00002423·100 enrolled

Show 8 more trials

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002369·200 enrolled

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002401·160 enrolled

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001095·94 enrolled

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002400·45 enrolled

A Study of 141W94 in Combination With Other Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 1·NCT00002372·48 enrolled

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000912·475 enrolled

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002440·80 enrolled

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

Completed·WWeill Medical College of Cornell University·N/A·NCT00002407

HIV9 trials

A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients

Completed·AAbbott·N/A·NCT00002223

The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000848·144 enrolled

A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002406·350 enrolled

Show 6 more trials

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002236·32 enrolled

A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001086·300 enrolled

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000841·1,750 enrolled

A Comparison of 141W94 and Indinavir in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 3·NCT00002202·460 enrolled

Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002220·120 enrolled

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002354·540 enrolled

HIV infection6 trials

Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006443·24 enrolled

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000870·200 enrolled

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

Completed· GSK logo

GSK·Phase 2·NCT00002233·30 enrolled

Show 3 more trials

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006154·165 enrolled

Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00006339

Treatment5 trials

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000903·444 enrolled

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000861·1,900 enrolled

A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001084·500 enrolled

Show 2 more trials

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000885·440 enrolled

Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00012519·29 enrolled

26 more indications

Tolerance1 trial

Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001133·50 enrolled

HIV-11 trial

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002155·600 enrolled

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002208·400 enrolled

Adult1 trial

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000877·31 enrolled

Safety and Efficacy1 trial

A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

Completed· GSK logo

GSK·Phase 3·NCT00002199·550 enrolled

Interaction1 trial

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00039975·32 enrolled

Kaposi's sarcoma1 trial

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003008·33 enrolled

HIV-1 infection1 trial

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000875·16 enrolled

Mycobacterium Avium Complex1 trial

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001058·246 enrolled

Drug Therapy1 trial

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000923·110 enrolled

Drug Interactions1 trial

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00005762·90 enrolled

HIV-Infected Individuals1 trial

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000859·1,300 enrolled

LAM1 trial

Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000882·300 enrolled

Women1 trial

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

Unknown status·PPPD Development, LP·Phase 3·NCT00006397·200 enrolled

Drug Resistance1 trial

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00027339·53 enrolled

Adolescent1 trial

A Study of L-735,524 in HIV-Positive Children and Adolescents

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00002351·12 enrolled

Hemophilia1 trial

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002386·55 enrolled

Children1 trial

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001083·240 enrolled

Transplantation1 trial

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001566·42 enrolled

Radiation Therapy1 trial

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Unknown status·OOncology Institute of Southern Switzerland·Phase 2·NCT00637637·60 enrolled

Treatment Failure1 trial

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000918·300 enrolled

Progesterone1 trial

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00016601·76 enrolled

Unspecified1 trial

A Study of Indinavir Taken With or Without DMP 266

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002393·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 80 trial records for Indinavir sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Crixivan drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Indinavir sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Indinavir sulfate. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Human Immunodeficiency Virus Type 1 Protease Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Merck & Co.

Crixivan

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Effectiveness23 trials

Drug11 trials

HIV9 trials

HIV infection6 trials

Treatment5 trials

Tolerance1 trial

HIV-11 trial

Pregnant Women1 trial

Immune System1 trial

Interleukin1 trial

Randomized1 trial

Adult1 trial

Safety and Efficacy1 trial

Interaction1 trial

Kaposi's sarcoma1 trial

HIV-1 infection1 trial

Mycobacterium Avium Complex1 trial

Drug Therapy1 trial

Drug Interactions1 trial

HIV-Infected Individuals1 trial

LAM1 trial

Women1 trial

Drug Resistance1 trial

Adolescent1 trial

Hemophilia1 trial

Children1 trial

Transplantation1 trial

Radiation Therapy1 trial

Treatment Failure1 trial

Progesterone1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News